{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:10:28Z","timestamp":1786374628148,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sentinel lymph node biopsy (SLNB) is the standard for axillary staging in early breast cancer, yet its relevance is increasingly questioned in patients with favorable tumor biology when nodal status does not influence systemic treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, single-center observational study including 162 women with clinically and sonographically node-negative (cN0) pT1 invasive breast cancer treated between 2019 and 2024 at a French university hospital. All patients underwent axillary staging and had complete molecular profiling. Among the 25 patients with pathologically positive nodes (pN+), two multidisciplinary team (MDT) discussions were simulated: one blinded to nodal status (limited-information MDT) and one with complete clinicopathologic data (full-information MDT). Recommendations for adjuvant chemotherapy and genomic testing (Oncotype DX) were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most tumors were hormone receptor\u2013positive (90%) and HER2-negative (87%); 9% were triple-negative. Despite negative preoperative axillary ultrasound, nodal involvement was identified in 25 patients (15%). In the limited-information MDT, chemotherapy was recommended in 8 patients and genomic testing in 11 patients. In contrast, the full-information MDT recommended chemotherapy in 16 patients and genomic testing in 9 patients, with 2 additional patients ultimately receiving chemotherapy. Omission of nodal status during MDT deliberation was associated with a significant reduction in chemotherapy recommendations (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Genomic testing contributed to treatment de-escalation in both scenarios.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In selected patients with pT1 breast cancer, omission of axillary nodal status during MDT decision-making may safely reduce adjuvant chemotherapy use without compromising treatment planning, supporting current axillary de-escalation strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06498-6","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:05:03Z","timestamp":1780571103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["De-escalating axillary surgery in early breast cancer: external validation of a retrospective cohort"],"prefix":"10.1007","volume":"152","author":[{"given":"Mathilde","family":"Landry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Favier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feriel","family":"Ksantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gabro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffroy","family":"Canlorbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Uzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"5","key":"6498_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. JNCI J Natl Cancer Inst 3 mars 85(5):365\u2013376","journal-title":"JNCI J Natl Cancer Inst 3 mars"},{"issue":"10","key":"6498_CR4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1055\/a-1904-6231","volume":"82","author":"M Banys-Paluchowski","year":"2022","unstructured":"Banys-Paluchowski M, Thill M, K\u00fchn T, Ditsch N, Heil J, W\u00f6ckel A et al (2022) AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022. Geburtshilfe Frauenheilkd oct 82(10):1031\u20131043","journal-title":"Geburtshilfe Frauenheilkd oct"},{"issue":"7","key":"6498_CR1","first-page":"726","volume":"70","author":"S Dabakuyo-Yonli","year":"2020","unstructured":"Dabakuyo-Yonli S, Arveux P (2020) [Epidemiology of breast cancer]. Rev Prat sept 70(7):726\u2013729","journal-title":"Rev Prat sept"},{"key":"6498_CR26","doi-asserted-by":"crossref","unstructured":"Dabi Y, Thubert T, Fuchs F, Barjat T, Belaisch-Allart J, Ceccaldi PF (2022) Members of the CEROG committee. How is functionning the Ethical Review Board \u00ab Comit\u00e9 d\u2019Ethique pour la Recherche en Obst\u00e9trique et Gyn\u00e9cologie \u00bb (CEROG) ? J Gynecol Obstet Hum Reprod. 2022 2:102352.","DOI":"10.1016\/j.jogoh.2022.102352"},{"key":"6498_CR16","doi-asserted-by":"publisher","first-page":"5909724","DOI":"10.1155\/2022\/5909724","volume":"2022","author":"FE de Jongh","year":"2022","unstructured":"de Jongh FE, Efe R, Herrmann KH, Spoorendonk JA (2022) Cost and Clinical Benefits Associated with Oncotype DX\u00ae Test in Patients with Early-Stage HR+\/HER2- Node-Negative Breast Cancer in the Netherlands. Int J Breast Cancer 2022:5909724","journal-title":"Int J Breast Cancer"},{"issue":"2","key":"6498_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA (2004) Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey. Ann Surg ao\u00fbt 240(2):205\u2013213","journal-title":"Ann Surg ao\u00fbt"},{"issue":"8","key":"6498_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa020128","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347(8):567\u2013575","journal-title":"N Engl J Med"},{"issue":"11","key":"6498_CR9","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","volume":"9","author":"OD Gentilini","year":"2023","unstructured":"Gentilini OD, Botteri E, Sangalli C, Galimberti V, Porpiglia M, Agresti R et al (2023) Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol 1 nov 9(11):1557","journal-title":"JAMA Oncol 1 nov"},{"issue":"10","key":"6498_CR7","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"12","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 12(10):918","journal-title":"JAMA"},{"key":"6498_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.suronc.2020.08.020","volume":"35","author":"MM G\u00e1lvez","year":"2020","unstructured":"G\u00e1lvez MM, Jim\u00e9nez JA, Gil Izquierdo JI, Alcaraz AC, Benito AC, Gonz\u00e1lez LC et al (2020) Ultrasound staging in breast cancer: A decision-making oriented approach to axillary metastatic burden prediction. Surg Oncol d\u00e9c 35:114\u2013119","journal-title":"Surg Oncol d\u00e9c"},{"issue":"10","key":"6498_CR21","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1245\/s10434-016-5398-6","volume":"23","author":"J Gunn","year":"2016","unstructured":"Gunn J, Gibson T, Li Z, Diehl N, Bagaria S, McLaughlin S (2016) Symptomatic Axillary Seroma after Sentinel Lymph Node Biopsy: Incidence and Treatment. Ann Surg Oncol oct 23(10):3347\u20133353","journal-title":"Ann Surg Oncol oct"},{"issue":"2","key":"6498_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10549-025-07661-2","volume":"211","author":"R Han","year":"2025","unstructured":"Han R, Brogi E, Thompson D, El-Tamer M, Morrow M, Wen HY (2025) Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience. Breast Cancer Res Treat juin 211(2):449\u2013454","journal-title":"Breast Cancer Res Treat juin"},{"issue":"3","key":"6498_CR3","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/annonc\/mdt532","volume":"25","author":"G Houvenaeghel","year":"2014","unstructured":"Houvenaeghel G, Goncalves A, Classe JM, Garbay JR, Giard S, Charytensky H et al (2014) Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study. Ann Oncol Off J Eur Soc Med Oncol mars 25(3):623\u2013628","journal-title":"Ann Oncol Off J Eur Soc Med Oncol mars"},{"issue":"6","key":"6498_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","volume":"27","author":"N Howlader","year":"2018","unstructured":"Howlader N, Cronin KA, Kurian AW, Andridge R (2018) Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol Biomarkers Prev 1 juin 27(6):619\u2013626","journal-title":"Cancer Epidemiol Biomarkers Prev 1 juin"},{"issue":"2","key":"6498_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ et al (2024) Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol f\u00e9vr 35(2):159\u2013182","journal-title":"Ann Oncol f\u00e9vr"},{"issue":"19","key":"6498_CR19","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"9","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P et al (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 9(19):1836\u20131846","journal-title":"N Engl J Med"},{"issue":"9132","key":"6498_CR15","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","volume":"352","author":"Polychemotherapy for early","year":"1998","unstructured":"Polychemotherapy for early (1998) breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists\u2019 Collaborative Group. Lancet Lond Engl 19 sept 352(9132):930\u2013942","journal-title":"Lancet Lond Engl 19 sept"},{"issue":"1","key":"6498_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-023-07203-8","volume":"205","author":"S Prathibha","year":"2024","unstructured":"Prathibha S, White M, Kolbow M, Hui JYC, Brauer D, Ankeny J et al (2024) Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes. Breast Cancer Res Treat mai 205(1):127\u2013133","journal-title":"Breast Cancer Res Treat mai"},{"issue":"4","key":"6498_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000509846","volume":"15","author":"J Puppe","year":"2020","unstructured":"Puppe J, Seifert T, Eichler C, Pilch H, Mallmann P, Malter W (2020) Genomic Signatures in Luminal Breast Cancer. Breast Care Basel Switz ao\u00fbt 15(4):355\u2013365","journal-title":"Breast Care Basel Switz ao\u00fbt"},{"issue":"11","key":"6498_CR10","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","volume":"392","author":"T Reimer","year":"2025","unstructured":"Reimer T, Stachs A, Veselinovic K, K\u00fchn T, Heil J, Polata S et al (2025) Axillary surgery in breast cancer - primary results of the INSEMA trial. N Engl J Med 392(11):1051\u20131064","journal-title":"N Engl J Med"},{"issue":"2","key":"6498_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111\u2013121","journal-title":"N Engl J Med"},{"issue":"10","key":"6498_CR24","doi-asserted-by":"publisher","first-page":"110392","DOI":"10.1016\/j.ejso.2025.110392","volume":"51","author":"N Tauber","year":"2025","unstructured":"Tauber N, Rambow AC, Gasthaus C, Fick F, Grande-Nagel I, Hilmer L et al (2025) Axillary surgery in early breast cancer: real-world analysis of the INSEMA-trial at three certified university breast cancer centers in Germany regarding the omission of sentinel lymph node biopsy. Eur J Surg Oncol oct 51(10):110392","journal-title":"Eur J Surg Oncol oct"},{"issue":"1","key":"6498_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-014-2846-5","volume":"144","author":"H Verbelen","year":"2014","unstructured":"Verbelen H, Gebruers N, Eeckhout FM, Verlinden K, Tjalma W (2014) Shoulder and arm morbidity in sentinel node-negative breast cancer patients: a systematic review. Breast Cancer Res Treat f\u00e9vr 144(1):21\u201331","journal-title":"Breast Cancer Res Treat f\u00e9vr"},{"issue":"4","key":"6498_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1245\/ASO.2006.05.013","volume":"13","author":"LG Wilke","year":"2006","unstructured":"Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM et al (2006) Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial. Ann Surg Oncol avr 13(4):491\u2013500","journal-title":"Ann Surg Oncol avr"},{"issue":"5","key":"6498_CR25","doi-asserted-by":"publisher","first-page":"znaf031","DOI":"10.1093\/bjs\/znaf031","volume":"112","author":"VM Van Wintraecken","year":"2025","unstructured":"Wintraecken VM, Van Roozendaal LM, Simons JM, De Vries J, Van Kuijk SMJ, Vane MLG et al (2025) Three-year patient-reported outcomes of the BOOG 2013-08 RCT evaluating omission of sentinel lymph node biopsy in early-stage breast cancer patients treated with breast conserving surgery: impact of personality traits on health-related quality of life. Br J Surg 112(5):znaf031","journal-title":"Br J Surg"},{"key":"6498_CR2","doi-asserted-by":"publisher","first-page":"636266","DOI":"10.3389\/fonc.2021.636266","volume":"11","author":"S Zhu","year":"2021","unstructured":"Zhu S, Li Y, Chen W, Fei X, Shen K, Chen X (2021) Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment. Front Oncol 11:636266","journal-title":"Front Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06498-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:03:13Z","timestamp":1786370593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06498-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["6498"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06498-6","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"158"}}